Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Deloitte
US Army
Moodys
AstraZeneca
Citi

Generated: August 19, 2019

DrugPatentWatch Database Preview

Citalopram hydrobromide - Generic Drug Details

  Try a free trial


See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for citalopram hydrobromide and what is the scope of citalopram hydrobromide patent protection?

Citalopram hydrobromide is the generic ingredient in two branded drugs marketed by Mylan Pharms Inc, Forest Labs, Aurobindo Pharma Ltd, Hetero Labs Ltd Iii, Lannett Co Inc, Pd Partners, West-ward Pharms Int, Biovail Labs Intl, Allergan Sales Llc, Acp Nimble, Amneal Pharms Ny, Apotex Inc, Aurobindo, Chartwell Molecular, Dr Reddys Labs Ltd, Epic Pharma, Epic Pharma Llc, Fosun Pharma, Glenmark Generics, Heritage Pharma, Invagen Pharms, Jubilant Generics, Mylan, Natco Pharma Ltd, Roxane, Sun Pharm Inds Inc, Sun Pharm Industries, Taro, Torpharm, and Torrent Pharms, and is included in thirty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are fifty-six drug master file entries for citalopram hydrobromide. Sixty-eight suppliers are listed for this compound.

Pharmacology for citalopram hydrobromide
Medical Subject Heading (MeSH) Categories for citalopram hydrobromide
Synonyms for citalopram hydrobromide
(S)-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromide
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrobromide
1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile monohydrobromide
1-(3-(dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile monohydrobromide
1-(3-(Dimethylamino)propyl)-1,-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile monohydrobromide
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile hydrobromide
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile
1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile hydrobromide
1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile Hydrobromide
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile hydrobromide
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile;hydrobromide
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-isobenzofuran-5-carbonitrile hydrobromide
4CH-017662
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-, monohydrobromide
5-Isobenzofurancarbonitrile, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydro-,monohydrobromide
59729-32-7
729C327
A832439
AB0107058
AB1010898
AB10921
AC-1595
AC1L2U9E
AK-72795
AKOS005145738
AN-14765
ANW-42935
Apertia
API0006328
ARK092
AX8121801
BC207875
BCP9000537
BG0143
Bonitrile HBr
BR-72795
C 7861
C20H21FN2O.HBr
CCG-101022
CCG-213271
Celexa
Celexa (TN)
CHEMBL1200781
Cipramil
Citalopram (hydrobromide)
Citalopram for system suitability, European Pharmacopoeia (EP) Reference Standard
Citalopram HBr
Citalopram hydrobromide (USAN)
Citalopram hydrobromide [USAN:USP]
Citalopram hydrobromide [USAN]
Citalopram Hydrobromide 0.1 mg/ml in Methanol (as free base)
Citalopram Hydrobromide 1.0 mg/ml in Methanol (as free base)
Citalopram hydrobromide solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
Citalopram hydrobromide solution, 100 mug/mL in methanol (as free base), ampule of 1 mL, certified reference material
Citalopram hydrobromide, >=98% (HPLC)
Citalopram hydrobromide, European Pharmacopoeia (EP) Reference Standard
Citalopram Hydrobromide, Pharmaceutical Secondary Standard; Certified Reference Material
Citalopram hydrobromide, United States Pharmacopeia (USP) Reference Standard
CITALOPRAM, HYDROBROMIDE SALT
CPD000326936
CS-4735
CTK8B3679
D00822
DTXSID40872344
EINECS 261-890-6
Elopram
EU-0100258
FT-0600173
HSDB 7042
HY-B1287
I06-0616
J10477
KS-00000FXR
KS-1043
LP00258
LS-84329
Lu 10-171 HBr
Lu 10-171-B
Lu-10-171B
LU-10171B
Lupram
MFCD02101306
MLS000758293
MLS000860078
MLS001401376
MLS002222294
MolPort-003-940-770
NC00272
NCGC00093717-01
NCGC00093717-02
NCGC00093717-03
NCGC00260943-01
Nitalapram HBr
NSC-758684
NSC758684
Pharmakon1600-01504172
Prepram HBr
Prisdal
Q-200865
recital hydrobromide
RP17855
s4749
SAM001246599
SAM001247086
SC-18021
SCHEMBL1118
Sepram
Seropram
SMR000326936
SR-01000003129
SR-01000003129-10
SR-01000003129-2
SR-01000003129-4
ST2403129
TL8003797
Tox21_500258
TR-020691
W-105304
WIHMBLDNRMIGDW-UHFFFAOYSA-N
Z1550648760
ZD 211; LU 10-171
ZD-211

US Patents and Regulatory Information for citalopram hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Heritage Pharma CITALOPRAM HYDROBROMIDE citalopram hydrobromide TABLET;ORAL 077033-002 Oct 28, 2004 DISCN No No   Try a Free Trial   Try a Free Trial   Try a Free Trial
Mylan CITALOPRAM HYDROBROMIDE citalopram hydrobromide TABLET;ORAL 077039-003 Feb 3, 2005 DISCN No No   Try a Free Trial   Try a Free Trial   Try a Free Trial
Natco Pharma Ltd CITALOPRAM HYDROBROMIDE citalopram hydrobromide TABLET;ORAL 077141-002 Apr 10, 2008 DISCN No No   Try a Free Trial   Try a Free Trial   Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
QuintilesIMS
Merck
Mallinckrodt
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.